(Q45242460)

11 December 2017

Use of 6-mercaptopurine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease: balance (English)

1 reference

11 December 2017

1 reference

2

Robert N Baldassano

1 reference

11 December 2017

Douglas A Jacobstein

1

1 reference

11 December 2017

1 February 2005

1 reference

Inflammatory Bowel Diseases

11 December 2017

1 reference

11 December 2017

11

1 reference

11 December 2017

2

1 reference

11 December 2017

203-205

1 reference

A controlled double blind study of azathioprine in the management of Crohn's disease

11 December 2017

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200502000-00016

Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200502000-00016

Treatment of inflammatory bowel disease in childhood: best available evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200502000-00016

Postoperative outcome of Crohn's disease in 30 children

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200502000-00016

Morbidity of juvenile onset inflammatory bowel disease: effects on education and employment in early adult life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200502000-00016

The clinical pharmacology of 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200502000-00016

TPMT in the treatment of Crohn's disease with azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200502000-00016

10.1097/00054725-200502000-00016

21 January 2018

Identifiers

DOI

1 reference

11 December 2017

1 reference

PubMed ID

15677916